Taken from the Urologix 2003 Annual Report
Competition
Competition
in the market for the treatment of BPH comes from invasive therapies, such as
TURP, drug therapy and other minimally invasive treatments. There are six
well-recognized prescription drugs available in the
Competition
in the market for minimally invasive treatments for BPH continues to grow.
Competitive
devices include radio frequency (Medtronic), interstitial laser (Johnson &
Johnson), side-firing laser (Laserscope), non-cooled, low energy microwave (TherMatrx,
Inc.), high energy microwave with limited cooling (ACMI) and water-induced thermotherapy (ACMI). Celsion
Corporation formed a strategic alliance with Boston Scientific Corporation for
Boston Scientific to distribute a new microwave system for BPH upon approval
from the FDA to market the device. Additional competitors may enter the market.
We believe Cooled ThermoTherapy provides significant
advantages over other minimally invasive BPH therapies. Because Cooled ThermoTherapy does not require punctures or incisions, it
can be performed in the physician’s office or other outpatient environments without
the need for anesthesia or intravenous sedation. Further, by combining
microwave energy with cooling, we can drive heat deep into the prostate,
creating lasting results while minimizing damage to the urethra, enhancing
patient comfort and reducing complications.